Join the Wegovy group to help and get support from people like you.
Wegovy News
GLP-1 Receptor Agonists Tied to Reduced Mortality in Patients With Psoriasis
TUESDAY, Sept. 30, 2025 – Patients with psoriasis treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have better long-term outcomes compared with those taking other diabetes or...
Oral Semaglutide Effective for Weight Loss in Overweight or Obesity
THURSDAY, Sept. 25, 2025 – Oral semaglutide (25 mg) is effective for weight loss in adults with overweight or obesity without diabetes, according to a study published online Sept. 17 in the New...
Ozempic Pill Effective For Weight Loss
WEDNESDAY, Sept. 24, 2025 — A pill form of the blockbuster weight-loss drug Ozempic can help overweight or obese folks shed excess pounds, a new clinical trial has concluded. People who took a daily s...
GLP-1 Receptor Agonists Improve Glycemic, Weight Outcomes in Children With T2D
TUESDAY, Sept. 23, 2025 – In children and adolescents with type 2 diabetes (T2D) or obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycemic, weight, and cardiometabolic...
GLP-1 Pill, Orforglipron, Effective For Weight Loss, Clinical Trials Show
FRIDAY, Sept. 19, 2025 — An effective weight-loss pill to rival injectable drugs like Ozempic and Zepbound might be on the horizon, clinical trial results show. An experimental GLP-1 pill called o...
Weight-Loss Surgery Outperforms GLP-1 Drugs, Study Argues
FRIDAY, Sept. 19, 2025 — Cutting-edge drugs like Ozempic and Zepbound are all the rage for dropping excess pounds, but weight-loss surgery might have a better impact on people’s health, a new study sa...
Once-Weekly Semaglutide 7.2 mg Beats Placebo for Obesity
THURSDAY, Sept. 18, 2025 – In adults with obesity and those with type 2 diabetes and obesity, once-weekly semaglutide 7.2 mg is superior to placebo for body weight reduction, according to two...
FDA Cracks Down on Hims, Other Telehealth Companies Over Drug Ads
WEDNESDAY, Sept. 17, 2025 — Federal health officials are cracking down on telehealth companies’ promotion of unapproved versions of prescription drugs, including popular weight loss medications. On Tu...
GLP-1 RAs Cost-Effective Versus Usual Care for Knee OA, Obesity
WEDNESDAY, Sept. 17, 2025 – Compared with usual care, the glucagon-like peptide 1 receptor agonists (GLP-1 RAs) tirzepatide and semaglutide are cost-effective for people with knee osteoarthritis...
Wegovy May Help Quiet Constant Food Cravings, Study Finds
WEDNESDAY, Sept. 17, 2025 — A popular weight-loss drug may do more than help patients shed pounds. It could also help quiet the nonstop food cravings many people struggle with. New results from a U...
Triple Dose Of Ozempic Safe, More Effective For Weight Loss
TUESDAY, Sept. 16, 2025 — A triple-sized weekly dose of Ozempic works better to help people with obesity shed excess pounds without significant side effects, new clinical trial results show. Obese f...
Half Discontinue Semaglutide for Weight Loss Within One Year
TUESDAY, Sept. 16, 2025 – Half of adults who start semaglutide for weight loss discontinue within a year, according to a study presented at the annual meeting of the European Association for the...
Half Of Ozempic Weight-Loss Users Drop The Drug Within A Year
MONDAY, Sept. 15, 2025 — Half of people who start taking the GLP-1 weight-loss drug Ozempic drop it within a year, a new study says. About 52% of people in Denmark prescribed semaglutide (Ozempic, W...
WHO Updates List of Essential Medicines to Include GLP-1s
TUESDAY, Sept. 9, 2025 – The World Health Organization published updated editions of its Model List of Essential Medicines (EML) and Essential Medicines for Children (EMLc) to include new treatments...
FDA Creates 'Green List' of GLP-1 Drug Ingredients Approved for Entry in the U.S.
FRIDAY, Sept. 5, 2025 -- The U.S. Food and Drug Administration has created a "green list" import alert to stop unapproved and unverified glucagon-like peptide 1 (GLP-1) drug ingredients from entering ...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Cardiovascular Risk Reduction, Nonalcoholic Fatty Liver Disease